Palatin Technologies (PTN) Receives NYSE Non-compliance Notice
Get Alerts PTN Hot Sheet
Join SI Premium – FREE
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Palatin was not in compliance with the Exchange's continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders' equity
Palatin intends to timely deliver a Plan to the Exchange. If the Exchange accepts the Plan, Palatin will be able to continue its listing during the Plan period and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan until it has regained compliance. Palatin is assessing and exploring multiple funding avenues and is committed to undertaking a transaction or transactions in the future to achieve compliance with the Exchange's requirements.
Receipt of the notice from the Exchange has no immediate effect on the listing or trading of Palatin's common stock on the Exchange, and does not affect Palatin's business, operations or reporting requirements with the U.S. Securities and Exchange Commission.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dubai's VARA and Securitize sign MoU on tokenized markets
- Vishay launches thin film chip resistors for high frequency use
- Planet Labs signs 7-figure deal with European defense customer
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share